0KHE Stock Chart & Stats
$128.26
-$2.42(-2.17%)
At close: 4:00 PM EDT
$128.26
-$2.42(-2.17%)
Day’s Range― - ―
52-Week Range$80.00 - $132.45
Previous CloseN/A
Volume7.00
Average Volume (3M)114.00
Market Cap
$14.53B
Enterprise Value$15.02K
Total Cash (Recent Filing)$1.02B
Total Debt (Recent Filing)$3.34B
Price to Earnings (P/E)62.0
Beta0.94
Next Earnings
Nov 02, 2026EPS Estimate
1.29Next Dividend Ex-DateN/A
Dividend Yield0.21%
Share Statistics
EPS (TTM)2.10
Shares Outstanding111,586,400
10 Day Avg. Volume105
30 Day Avg. Volume114
Financial Highlights & Ratios
PEG Ratio-3.41
Price to Book (P/B)1.52
Price to Sales (P/S)3.85
P/FCF Ratio21.63
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$124.00Price Target Upside-3.32% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)5.35
Revenue Forecast (FY)$2.85B
Bulls Say, Bears Say
Bulls Say
Diagnostics GrowthStrong Diagnostics growth across reproductive health and immunodiagnostics supports a durable position in clinical testing. Continued demand for essential laboratory workflows can diversify results beyond more cyclical research spending.
Cash Generation And Balance SheetRobust free cash flow and improving leverage provide financial flexibility for product investment, acquisitions and debt reduction. Strong cash conversion also helps Revvity absorb fluctuations in research demand without relying heavily on external capital.
Installed-Base And Software ExpansionRecurring software, services and consumables tied to Revvity's installed instruments can improve revenue visibility and customer retention. Signals product launches and ACD/Labs integration expand the informatics offering and support longer-term workflow value.
Bears Say
Margin CompressionRecent profitability remains solid, but margins are below prior-cycle levels and historical earnings have been volatile, including a 2023 net loss. Sustained margin recovery is therefore important to demonstrate that growth is translating into durable shareholder returns.
Life Sciences And Software WeaknessWeakness in Life Sciences and volatile Signals revenue expose Revvity to uneven pharmaceutical, biotech and research-lab spending. Contract timing and difficult comparisons may ease, but continued softness would pressure growth and reduce confidence in software scalability.
Portfolio And Geographic ChallengesThe planned divestiture reflects structurally difficult conditions in China's immunodiagnostics market and will reduce geographic and portfolio exposure. Until closing, execution and regulatory approvals remain relevant, while the business continues affecting reported results.
Revvity News
0KHE FAQ
What was Revvity’s price range in the past 12 months?
Revvity lowest share price was $80.00 and its highest was $132.45 in the past 12 months.
What is Revvity’s market cap?
Revvity’s market cap is $14.53B.
When is Revvity’s upcoming earnings report date?
Revvity’s upcoming earnings report date is Nov 02, 2026 which is in 57 days.
How were Revvity’s earnings last quarter?
Revvity released its earnings results on Aug 04, 2026. The company reported $1.41 earnings per share for the quarter, beating the consensus estimate of $1.214 by $0.196.
Is Revvity overvalued?
According to Wall Street analysts Revvity’s price is currently Overvalued.
Does Revvity pay dividends?
Revvity pays a Quarterly dividend of $0.07 which represents an annual dividend yield of 0.21%. See more information on Revvity dividends here
What is Revvity’s EPS estimate?
Revvity’s EPS estimate is 1.29.
How many shares outstanding does Revvity have?
Revvity has 111,586,400 shares outstanding.
What happened to Revvity’s price movement after its last earnings report?
Revvity reported an EPS of $1.41 in its last earnings report, beating expectations of $1.214. Following the earnings report the stock price went down -3.071%.
Which hedge fund is a major shareholder of Revvity?
Currently, no hedge funds are holding shares in GB:0KHE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Revvity Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$124.00 (-3.32% Downside)
$124.00 (-3.32% Downside)
Blogger Sentiment
Neutral
GB:0KHE Sentiment 63%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
52.37%
12-Months-Change
Fundamentals
Return on Equity
0.21%
Trailing 12-Months
Asset Growth
-2.56%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Revvity
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
0KHE Company Deck
0KHE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a generally positive operational and financial picture: revenue and EPS beat with upgraded full-year guidance, strong Diagnostics performance, accelerating high-content instrument orders and robust cash flow and balance sheet improvements. Key near-term weaknesses include a sizable decline in Signals software revenue this quarter, some production/timing constraints that shifted instrument revenue into Q3, and portions of the quarter's outperformance tied to one-time tariff refunds and tax timing. Management plans reinvestments of a portion of one-time benefits while highlighting new software capabilities and AI-driven demand as multi-year growth drivers—though the AI opportunity is still early and not fully quantifiable.View all GB:0KHE earnings summaries0KHE Revenue Breakdown
50.11% Life sciences
49.89% Diagnostics
0KHE Stock 12 Month Forecast
Average Price Target
$124.00
▼(-3.32% Downside)